Looking to publish in Cardiovascular Drugs and Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowCardiovascular Drugs and Therapy is dedicated to the development of cardiovascular drug, device, and cell therapy from bench to bedside. It focuses on advances in hyperlipidemia, diabetes and other cardiometabolic conditions, atherosclerosis, ischemic syndromes, heart failure, cardiomyopathies, valvular heart disease, arrhythmias, mechanisms of action and signaling pathways, new drug development, novel indications for older drugs, genetic approaches to treatment, and new directions in device and cell therapy, interventional and structural heart disease, and cardiac and vascular surgery, as well as guideline-based utilization in real-world patient populations.
Looking to publish in Cardiovascular Drugs and Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Cardiovascular Drugs and Therapy accepts the following article types. Click on an article type to view submission instructions.
Original Research Articles
Review Articles
Short Communications
Letters To The Editor
Recent Publications
Anatomophysiopathology of Vein Graft Arterialization: The Potential Damage of Venous Valves
José Glauco Lobo Filho, Heraldo Guedis Lobo Filho, Matheus Duarte Pimentel
Beyond Branch Patency: Timing, Bleeding Phenotype, and Organ Risk in Antithrombotic Therapy After Branched EVAR
Jiaqian Ying
Effects of Dapagliflozin Combined with Sacubitril/Valsartan on Cardiac Electrophysiology and Quantitative Myocardial Motion Parameters in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction
Tao Wang, Xiaoli Chen, Huimin Wang, Mengyu Zhang
Citrated Kaolin Reaction Time on Thromboelastography 6s Identifies Bleeding-Prone Phenotypes in Older Adults with Atrial Fibrillation Receiving Direct Oral Anticoagulant Therapy
Jin Kyung Hwang, Su Hyun Lee, Sung Joo Cha, Chee Hae Kim, Chang Hoon Lee
Aspirin Instead of Clopidogrel after Percutaneous Coronary Intervention in Atrial Fibrillation: More than just an Option
Andrea Rubboli, Riccardo Panevino, Graziella Pompei
Frequently asked questions
How long does it take to publish?
All articles are reviewed by two or more referees. Accepted articles are published online after receipt of the corrected proofs.
Reformat to Cardiovascular Drugs and Therapy using Livewrite PremiumIs a cover letter required?
A submission letter is referenced for reviewer suggestions, unpublished material, and transparency on re-use of material.
Reformat to Cardiovascular Drugs and Therapy using Livewrite PremiumWhat are the publication costs?
Open access APC: £3090.00 GBP / $4690.00 USD / €3890.00 EUR. Subscription publishing has no APC charges.
Reformat to Cardiovascular Drugs and Therapy using Livewrite Premium